Clinical trials: Anti-Glaucoma Medications
Open Angle Glaucoma
A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction
The purpose of this study is to compare the safety and efficacy of goniotomy performed with a novel ophthalmic knife compared to trabecular bypass stent implantation in mild to moderate glaucoma subjects who are also undergoing…
- Trial name
- NCT02784249
- Testing
- Goniotomy, Trabecular Micro-Bypass Stent, Cataract Extraction
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- New World Medical, Inc.
Glaucoma
Glaucoma Treatment Using Focused Ultrasound in Open Angle Glaucoma Patients
The purpose of the this study is to collect safety and efficacy data on Focused Ultrasound treatment (UCP procedure) in open angle glaucoma patients without previous glaucoma surgery.
- Trial name
- NCT02789293
- Testing
- EyeOP1 device
- Where
- 4 sites in Belgium, Israel and 2 more
- Volunteers
- 80 people
- Sponsor
- EyeTechCare
Glaucoma
Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®
Phase I clinical study, to evaluate the safety and tolerability of the ophthalmic solution PRO-179 compared with Travatan®, on the ocular surface of clinically healthy subjects.
- Trial name
- PRO-179/I (NCT03965052)
- Testing
- PRO 179, Travatan 0.004 % Ophthalmic Solution
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Refractory Glaucoma
Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma
Real-world evidence study to assess the safety and effectiveness of XEN® Glaucoma Treatment System in Chinese patients with refractory glaucoma.
- Trial name
- NCT04303897
- Testing
- XEN Glaucoma Stent
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Allergan
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
- Trial name
- NCT02674854
- Testing
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Angle-Closure
Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
This study will evaluate the safety and IOP-lowering effectiveness of XEN in patients with Angle Closure Glaucoma.
- Trial name
- NCT03362931
- Testing
- XEN45
- Where
- 16 sites in Australia, Canada and 4 more
- Volunteers
- 65 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost.
- Trial name
- NCT01789736
- Testing
- PG286 Ophthalmic Solution 0.5%, AR-12286 Ophthalmic Solution 0.5%, Travoprost Ophthalmic Solution 0.004%
- Where
- 21 sites in United States
- Volunteers
- 234 people
- Sponsor
- Aerie Pharmaceuticals
Ocular Hypertension, Open Angle Glaucoma
Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost
- Trial name
- NCT01731002
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Where
- 22 sites in United States
- Volunteers
- 224 people
- Sponsor
- Aerie Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
Next Generation Rocklatan
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT06441643
- Testing
- AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 426 people
- Sponsor
- Alcon Research
Primary Open-Angle Glaucoma
GlaucoT Glaucoma Treatment Glasses in the Treatment of Primary Open-Angle Glaucoma
Glaucoma is a chronic and progressive optic neuropathy characterized by degeneration of ganglion cells and axons with loss of visual function.
- Trial name
- GlaucoT (NCT05253534)
- Testing
- GlaucoT Glaucoma Treatment Device
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Glaucot Teknoloji Anonim Sirketi
Glaucoma, Ocular Hypertension
AR-12286 in Combination With Latanoprost
This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).
- Trial name
- NCT01302249
- Testing
- Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
- Where
- 15 sites in United States
- Volunteers
- 66 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma
Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure
A 28 day study of the safety and efficacy of two concentrations of topical AR-12286 in treating ocular hypertension and open-angle glaucoma compared to latanoprost.
- Trial name
- NCT01060579
- Testing
- AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution
- Where
- 18 sites in United States
- Volunteers
- 217 people
- Sponsor
- Aerie Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
24-hour Efficacy of AR-12286
An open-label, non-comparative, pilot evaluation of the 24-hour ocular hypotensive efficacy of AR-12286 in patients with open-angle glaucoma or ocular hypertension
- Trial name
- NCT01330979
- Testing
- AR-12286 0.5% Ophthalmic Solution
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Aerie Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular…
- Trial name
- NCT03284853
- Testing
- Netarsudil/Latanoprost 0.02%/0.005%, GANFORT®
- Where
- 68 sites in Austria, Belgium and 9 more
- Volunteers
- 436 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04944290
- Testing
- Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 447 people
- Sponsor
- Padagis LLC
Ocular Hypertension, Open-angle Glaucoma
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%
- Trial name
- Rocket-1 (NCT02207491)
- Testing
- Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%
- Where
- United States
- Volunteers
- 411 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma
Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of Glaucoma
This is a prospective, observational, non-interventional study of patients scheduled to receive surgical intervention either via XEN or trabeculectomy for open-angle glaucoma.
- Trial name
- XENPRO (NCT03852810)
- Where
- 10 sites in Canada, Germany and 1 more
- Volunteers
- 28 people
- Sponsor
- Allergan
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.
- Trial name
- NCT02558374
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- United States
- Volunteers
- 708 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Ocular Hypertension
Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)
This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.
- Trial name
- NCT00108017
- Testing
- MK0507A, dorzolamide hydrochloride (+) timolol maleate, Comparator: timolol maleate, Duration of Treatment: Part 1) 6 wk timolol maleate run in
- Volunteers
- 330 people
- Sponsor
- Merck Sharp & Dohme LLC